Biome Australia Limited

BIO

AU0000184137

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:37 2024-05-13 EDT			5-day change	1st Jan Change
0.29 ^AUD	-6.45%		+3.57%	+41.46%

04-11	Biome Australia Logs 74% Revenue Increase in Fiscal Q3	MT
04-02	Biome Australia Logs First Positive Underlying Quarterly Cash Flow in Fiscal Q3	MT

Biome Australia Limited Reaffirms Revenue Guidance for the Full Year of Fiscal 2024

November 27, 2023 at 04:20 pm

Biome Australia Limited reaffirmed revenue guidance for the full year of fiscal 2024. The company remained on track to deliver its full-year revenue guidance for the fiscal year 2024 of $11.5 million.

Latest news about Biome Australia Limited

Biome Australia Logs 74% Revenue Increase in Fiscal Q3	04-10	MT
Biome Australia Logs First Positive Underlying Quarterly Cash Flow in Fiscal Q3	04-02	MT
Biome Australia Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-21	CI
Biome's Activated Probiotics Enters UK, Ireland; Shares Jump 10%	01-14	MT
Biome Australia Raises Fiscal 2024 Revenue Guidance	01-08	MT
Microbiome Health Company Biome Australia Limited Revises Earnings Guidance for 2024	01-07	CI
Biome Reports Surge in Half Year Sales Revenue	01-01	MT
Biome Australia Limited Reports Unaudited Revenue Results for the Second Quarter and Half Year of 2024	01-01	CI
Australian Shares Slide as Rate Cut Hopes Lose Steam	12-21	MT
Biome Australia to Launch Cholesterol-Lowering Probiotic; Shares Climb 6%	12-20	MT
4,262,808 Options of Biome Australia Limited are subject to a Lock-Up Agreement Ending on 30-NOV-2023.	11-29	CI
39,359,545 Ordinary Shares of Biome Australia Limited are subject to a Lock-Up Agreement Ending on 30-NOV-2023.	11-29	CI
Biome Australia Limited Reaffirms Revenue Guidance for the Full Year of Fiscal 2024	11-27	CI
Biome Australia Limited Reports Sales Results for the First Five Months Ended November 2023	11-27	CI
Biome Australia Sees Higher Sales in Fiscal Year 2024	23-10-09	MT
Biome Australia Limited Provides Sales Revenue Guidance for the Fiscal Year 2024	23-10-08	CI
Biome Australia Logs Record Q1 Sales	23-10-04	MT
Biome Australia Limited Announces Unaudited Sales Results for the First Quarter Ended September 2023	23-10-02	CI
Biome Australia Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-23	CI
Biome Australia Adds to Probiotic Range with Product Launch	23-08-07	MT
Biome Australia Limited Provides Update on Biome Lift Probiotic Clinical Trial	23-07-05	CI
Biome Australia Records 75% Jump in Fiscal 2023 Revenue; Shares Up 4%	23-07-03	MT
Biome Australia Limited Reports Unaudited Sales Results for the Fourth Quarter and Full Year of 2023	23-07-03	CI
Biome Australia Jumps 16% After Exceeding FY23 Sales Revenue Target	23-06-14	MT
Biome Australia Signs Corporate Advisory Mandate With Boutique Investment Manager	23-03-31	MT

Chart Biome Australia Limited

Duration

Period

More charts

Company Profile

Biome Australia Ltd is an Australia-based microbiome health company. The Company develops, licenses, commercializes and markets evidence-based live biotherapeutics (probiotics) and complementary medicines. It develops, manufactures, and distributes evidence-based products linking the gut and human health through the Company owned brands, such as Activated Nutrients and Activated Probiotics. Activated Nutrients offers a range of completely organic, plant-based, all in-one nutritional products. Activated Probiotics offers a range of clinically backed precision probiotics. Activated Probiotics provides live biotherapeutic products clinically proven to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema through randomized double-blind placebo-controlled trials. Activated Probiotics products include Biome Acne Probiotic, Biome Baby Probiotic, Biome Eczema Probiotic, and Biome Acne Probiotic.

Sector

Pharmaceuticals

Calendar

2024-07-22 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BIOME AUSTRALIA LIMITED	+41.46%	43.56M
ELI LILLY AND COMPANY	+29.98%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.52%	361B
MERCK & CO., INC.	+18.59%	329B
ABBVIE INC.	+4.07%	284B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+7.09%	166B

Other Pharmaceuticals